Scarica l'app Stockscreener
190.92
1.56%
-3.03
Precedente Chiudi:
$193.95
Aprire:
$191.57
Volume 24 ore:
662.05K
Relative Volume:
0.33
Capitalizzazione di mercato:
$40.92B
Reddito:
$742.00K
Utile/perdita netta:
$-1.37B
Rapporto P/E:
-26.99
EPS:
-7.0731
Flusso di cassa netto:
$-1.07B
1 W Prestazione:
-4.48%
1M Prestazione:
-6.31%
6M Prestazione:
+40.07%
1 anno Prestazione:
+291.63%
Intervallo 1D:
$190.12
$193.61
Intervallo di 1 settimana:
$180.49
$203.50
Portata 52W:
$47.28
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, MRNA, REGN, ARGX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
190.92 | 40.92B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
493.43 | 125.07B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.01 | 85.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
754.40 | 77.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.12 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-24 | Ripresa | Goldman | Buy |
| 2026-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2026-05-22 | Iniziato | Bernstein | Mkt Perform |
| 2026-05-18 | Ripresa | Truist | Buy |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
About 3% of U.S. patients with metastatic pancreatic cancer survive five years. A drug pair starts testing in patients. - Stock Titan
Revolution Medicines (NasdaqGS:RVMD) Stock Forecast & Analyst Predictions - Simply Wall Street
Revolution Medicines’ CDO Sandler sells $1.2m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 October By Investing.com - Investing.com UK
Revolution Medicines SVP Cislini sells $158,599 in shares By Investing.com - Investing.com Nigeria
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com South Africa
Revolution Medicines SVP Cislini sells $158,599 in shares - Investing.com
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com UK
Revolution Medicines SVP Jeff Cislini Sells 765 Shares Under 10b5-1 Trading Plan - Kalkine Media
Revolution Medicines (RVMD) counsel Jeff Cislini sold 765 shares at $207.3201 each under a trading plan. - Stock Titan
6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD). - Stock Titan
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com South Africa
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com Nigeria
Revolution Medicines officer Mancini sells $743k in stock - Investing.com
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com UK
Stock options are the source of 9,363 shares a Revolution Medicines (RVMD) officer proposes to sell. - Stock Titan
Revolution Medicines director Elizabeth Anderson sells $1.96m in stock - Investing.com
Revolution Medicines (RVMD) director exercises options for 5,070 shares and sells 10,143 shares. - Stock Titan
After three earlier sales, an officer proposes selling 587 more Revolution Medicines (RVMD) shares. - Stock Titan
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes - Yahoo Finance
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Canada
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Revolution Medicines chief development officer sells $67,940 in stock - Investing.com
Revolution Medicines officer sells $353,449 in shares - Investing.com
Revolution Medicines COO Margaret Horn sells $989,612 of common stock - Investing.com
Revolution Medicines’ senior advisor sells $1.1m in stock - Investing.com
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Revolution Medicines CFO Jack Anders sells $807,513 in stock - Investing.com
Revolution Medicines (RVMD) exec sells 1,774 shares, keeps 39,575 RSUs - Stock Titan
Revolution Medicines (RVMD) legal chief makes pre-set stock sale for taxes - Stock Titan
Revolution Medicines (RVMD) insider adds new sale after multimillion-dollar trades - Stock Titan
Revolution Medicines (RVMD) CFO sells shares under tax-driven plan - Stock Titan
Officer at Revolution Medicines (RVMD) plans 331-share sale - Stock Titan
Revolution Medicines officer plans $484K sale | RVMD SEC FilingForm 144 - Stock Titan
Officer at Revolution Medicines (NASDAQ: RVMD) plans 4,830-share stock sale after RSU vesting - Stock Titan
Over $16M in recent stock sales as Revolution Medicines (NASDAQ: RVMD) filer Mark A. Goldsmith plans another trade - Stock Titan
Revolution Medicines (RVMD) exec exercises options, sells stock - Stock Titan
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com Australia
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com Canada
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Revolution Medicines Inc Azioni (RVMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ALAN SANDLER | Officer |
Sep 29 '26 |
Proposed Sale |
201.74 |
6,309 |
1,272,778 |
0 |
| Sandler Alan B. | Chief Development Officer |
Sep 29 '26 |
Sale |
202.14 |
6,309 |
1,275,294 |
52,559 |
| Mancini Anthony | See Remarks |
Sep 25 '26 |
Option Exercise |
33.62 |
3,121 |
104,928 |
42,886 |
| Mancini Anthony | See Remarks |
Sep 25 '26 |
Sale |
200.54 |
3,121 |
625,885 |
39,765 |
| ANTHONY MANCINI | Officer |
Sep 25 '26 |
Proposed Sale |
199.86 |
9,363 |
1,871,289 |
0 |
| Cislini Jeff | SVP & General Counsel |
Sep 25 '26 |
Sale |
207.32 |
765 |
158,600 |
51,776 |
| ANTHONY MANCINI | Officer |
Sep 24 '26 |
Proposed Sale |
190.74 |
587 |
111,964 |
0 |
| Mancini Anthony | See Remarks |
Sep 24 '26 |
Sale |
200.00 |
587 |
117,400 |
39,765 |
| ANDERSON ELIZABETH M | Director |
Sep 22 '26 |
Sale |
193.04 |
10,143 |
1,958,016 |
4,333 |
| ANDERSON ELIZABETH M | Director |
Sep 22 '26 |
Option Exercise |
1.12 |
5,070 |
5,678 |
14,476 |
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):